Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV

Chad J. Achenbach, Kimberly K. Scarsi, Robert L. Murphy

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


In the past 15 years, improvements in the treatment of HIV infection have dramatically reduced morbidity and mortality. Nucleoside reverse transcriptase inhibitors are the backbone of combination antiretroviral therapy for the treatment of HIV. One of the recommended and commonly used therapies in this class is the once-daily fixed-dose combination of abacavir/lamivudine. Clinical studies and practice have shown these drugs to be potent, safe, and easy to use in a variety of settings; however, several recent reports have challenged the safety and efficacy claims among certain patient populations, including those at risk for cardiovascular disease and in those with high viral loads prior to treatment initiation. We reviewed abacavir/lamivudine as a treatment for HIV and discussed limitations of its use due to these controversial issues.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalAdvances in Therapy
Issue number1
StatePublished - Jan 2010


  • Abacavir
  • Antiretroviral therapy
  • Epzicom
  • HIV
  • Lamivudine
  • Nucleoside reverse transcriptase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV'. Together they form a unique fingerprint.

Cite this